Despite advances in care, #MultipleMyeloma remains complex and patients continue to face ongoing challenges. Research continues to explore diverse approaches aimed at addressing evolving patient needs. At the International Myeloma Society’s Annual Meeting, we’re sharing new data from our multiple myeloma research programs, including findings in relapsed/refractory multiple myeloma (RRMM). Learn more: https://bit.ly/4iEDcFb #IMS26
About us
Follow AbbVie's oncology page for global news and updates about our commitment to discover and develop therapies that aim to address the unmet needs of people affected by cancer. Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html
- Website
-
https://www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html
External link for AbbVie | Oncology
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
This year's International Association for the Study of Lung Cancer's World Conference on Lung Cancer brought the global oncology community together to explore the latest breakthroughs in #LungCancer research and the future of care. We're proud to contribute to that momentum through research on potential immunotherapies and antibody-drug conjugates, designed to address lung cancer from multiple angles at once and help improve outcomes for patients. Learn more about our approach in lung cancer: https://lnkd.in/eEgWCvUw #WCLC26
-
Advancing research in chronic lymphocytic leukemia (#CLL) is aimed at helping patients resume their daily routines, so they can potentially return to work, personal passions and reduce time spent in a hospital. Felice Bombaci shares the broader societal impact of new medical innovations: #LifeInFreedom #BloodCancerAwareness #BCAM2026
-
-
Informed by clinical evidence, global patient data, and insights from the 2026 European Hematology Association (EHA) Congress, our new European Insight Paper in partnership with the European CLL Association (ECLLA) addresses key gaps in chronic lymphocytic leukemia (#CLL) care. The report introduces a European Holistic Framework aimed at improving patient support during treatment-free periods. Read the full report: https://bit.ly/4czd6zu
-
-
Personalized care starts when a patient’s voice is heard. For Johannes, open dialogue with his care team helps ensure his treatment plan. This #WorldLeukemiaDay, we advocate for accessible health information that empowers patients to take charge of their care. [Video description: Johannes Förner, CLL Patient, discusses the impact of human-centered communication] #LifeInFreedom #BeLeukemiaAware #WLD26
-
We announced topline results from our Phase 3 study in patients with relapsed/refractory #MultipleMyeloma (RRMM). Full results to be shared at this year’s International Myeloma Society's Annual Meeting. Learn more: https://bit.ly/4qReMu7 #IMS26
-
At this year’s International Association for the Study of Lung Cancer's World Conference on Lung Cancer (WCLC), our team will present new data in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), reflecting our commitment to expand innovative approaches to patient care. Learn more: https://bit.ly/4qxAX8r #WCLC26
-
NEWS: The European Commission has granted marketing authorization of our medicine as part of a combination regimen for adult patients with relapsed/refractory (R/R) follicular #lymphoma (FL), developed in collaboration with Genmab. Learn more: https://bit.ly/4wsTgx5 [Video description: On-screen text reads, “Oncology News”]
-
NEWS: We’ve announced topline results from our Phase 3 trial in adult patients with relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL), developed in partnership with Genmab Learn more: https://bit.ly/44ID5jn
-
Recently we were on the ground in Stockholm for the European Hematology Association (EHA) (#EHA2026) Congress. Take an inside look at our collaborative efforts with colleagues across the hematology community, showcasing our global commitment to transforming blood cancer care. See how we are continuing our momentum in hematology: https://lnkd.in/eEgWCvUw